ABSTRACT
BACKGROUND: Enterococcus gallinarum is an infrequently intestinal symbiotic pathogen associated with nosocomial infection in immunocompromised individuals. To date, rare cases of pulmonary infection attributable to Enterococcus gallinarum were reported. Herein, we presented the first case of empyema resulting from Enterococcus gallinarum infection. CASE PRESENTATION: An 81-year-old male presented with fever and dyspnea upon admission. Chest CT scan and thoracic ultrasonography confirmed the presence of right pleural effusion. Thoracoscopy revealed extensive adhesion, purulent fluid, and necrotic materials within the thoracic cavity. Enterococcus gallinarum was identified through pleural effusion culture. The patient underwent an intrathoracic injection of urokinase along with thoracic drainage. Following surgery, He took oral linezolid for over one month. Undergoing comprehensive treatment, the patient exhibited favorable recovery. CONCLUSIONS: We reported the first case of empyema due to Enterococcus gallinarum infection. It should be suspected in patients with impaired immune function and invasive therapies, without responding to conventional anti-infectious treatment.
Subject(s)
Enterococcus , Gram-Positive Bacterial Infections , Humans , Male , Aged, 80 and over , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/diagnosis , Enterococcus/isolation & purification , Anti-Bacterial Agents/therapeutic use , Empyema, Pleural/microbiology , Empyema, Pleural/drug therapy , Empyema/microbiology , Empyema/drug therapy , Tomography, X-Ray Computed , Linezolid/therapeutic useABSTRACT
Pleural empyema can lead to significant morbidity and mortality despite chest drainage and antibiotic treatment, necessitating novel and minimally invasive interventions. Fusobacterium nucleatum is an obligate anaerobe found in the human oral and gut microbiota. Advances in sequencing and puncture techniques have made it common to detect anaerobic bacteria in empyema cases. In this report, we describe the case of a 65-year-old man with hypertension who presented with a left-sided encapsulated pleural effusion. Initial fluid analysis using metagenomic next-generation sequencing (mNGS) revealed the presence of Fusobacterium nucleatum and Aspergillus chevalieri. Unfortunately, the patient experienced worsening pleural effusion despite drainage and antimicrobial therapy. Ultimately, successful treatment was achieved through intrapleural metronidazole therapy in conjunction with systemic antibiotics. The present case showed that intrapleural antibiotic therapy is a promising measure for pleural empyema.
Subject(s)
Anti-Bacterial Agents , Empyema, Pleural , Fusobacterium nucleatum , Salvage Therapy , Humans , Male , Aged , Empyema, Pleural/drug therapy , Empyema, Pleural/microbiology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Fusobacterium nucleatum/drug effects , Fusobacterium nucleatum/isolation & purification , Fusobacterium nucleatum/genetics , Fusobacterium Infections/drug therapy , Fusobacterium Infections/complications , Fusobacterium Infections/microbiology , Metronidazole/therapeutic use , Metronidazole/administration & dosage , High-Throughput Nucleotide Sequencing , Treatment OutcomeABSTRACT
Community-acquired pneumonia can lead to a serious complication called empyema, which refers to pus within the pleural space. While it poses a significant threat to morbidity, particularly in children, it is fortunately not associated with high mortality rates. However, determining the best course of management for children, including decisions regarding antibiotic selection, administration methods, and treatment duration, remains a topic of ongoing debate. This scoping review aims to map the existing literature on empyema in children, including types of studies, microbiology, therapies (both antimicrobial and surgical) and patient outcomes. We systematically searched PubMed and SCOPUS using the terms "pediatric" (encompassing children aged 0 to 18 years) and "pleural empyema" to identify all relevant studies published since 2000. This search adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA ScR) checklist.A total of 127 studies was included. Overall, 15 attempted to compare medical treatments (alone or in combination with pleural drainage or fibrinolysis) with more invasive surgical approaches, and six studies compared diverse surgical interventions. However, the diversity of study designs makes it difficult to derive firm conclusions on the optimal approach to pediatric empyema. The heterogeneity in inclusion criteria, pharmacological/surgical approaches and settings limit the ability to draw definitive conclusions. Overall, 78 out of 10,896 children (0.7%) included in the review died, with mortality being higher in Asia and Africa. Our scoping review highlights important gaps regarding several aspects of empyema in children, including specific serotypes of the most common bacteria involved in the etiology, the optimal pharmacological and surgical approach, and the potential benefits of newer antibiotics with optimal lung penetration. New trials, designed on a multi-country level a higher number of patients and more rigorous inclusion criteria and designs, should be urgently funded.
Subject(s)
Empyema, Pleural , Adolescent , Child , Child, Preschool , Humans , Infant , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/therapy , Drainage , Empyema, Pleural/therapy , Empyema, Pleural/microbiologyABSTRACT
Pleural empyema is a serious complication of pneumonia in children. Negative bacterial cultures commonly impede optimal antibiotic therapy. To improve bacterial identification, we developed a molecular assay and evaluated its performance compared with bacterial culture. Our multiplex-quantitative PCR to detect Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and Haemophilus influenzae was assessed using bacterial genomic DNA and laboratory-prepared samples (n = 267). To evaluate clinical performance, we conducted the Molecular Assessment of Thoracic Empyema (MATE) observational study, enrolling children hospitalised with empyema. Pleural fluids were tested by bacterial culture and multiplex-qPCR, and performance determined using a study gold standard. We determined clinical sensitivity and time-to-organism-identification to assess the potential of the multiplex-qPCR to reduce the duration of empiric untargeted antibiotic therapy. Using spiked samples, the multiplex-qPCR demonstrated 213/215 (99.1%) sensitivity and 52/52 (100%) specificity for all organisms. During May 2019-March 2023, 100 children were enrolled in the MATE study; median age was 3.9 years (IQR 2-5.6). A bacterial pathogen was identified in 90/100 (90%) specimens by multiplex-qPCR, and 24/100 (24%) by bacterial culture (P <0.001). Multiplex-qPCR identified a bacterial cause in 68/76 (90%) culture-negative specimens. S. pneumoniae was the most common pathogen, identified in 67/100 (67%) specimens. We estimate our multiplex-qPCR would have reduced the duration of untargeted antibiotic therapy in 61% of cases by a median 20 days (IQR 17.5-23, range 1-55). Multiplex-qPCR significantly increased pathogen detection compared with culture and may allow for reducing the duration of untargeted antibiotic therapy.
Subject(s)
Empyema, Pleural , Multiplex Polymerase Chain Reaction , Humans , Child, Preschool , Empyema, Pleural/microbiology , Empyema, Pleural/drug therapy , Empyema, Pleural/diagnosis , Male , Female , Multiplex Polymerase Chain Reaction/methods , Child , Haemophilus influenzae/genetics , Haemophilus influenzae/isolation & purification , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/isolation & purification , Streptococcus pyogenes/genetics , Streptococcus pyogenes/isolation & purification , Infant , Hospitalization , Anti-Bacterial Agents/therapeutic use , Sensitivity and Specificity , DNA, Bacterial/geneticsABSTRACT
We report a patient with fever and cough for 2 months who was finally given a diagnosis of alveolar-pleural fistula due to aspergillus empyema. We successfully closed the alveolar-pleural fistula with a ventricular septal defect occluder through bronchoscopy. Endoscopic closure of an alveolar-pleural fistula with ventricular septal defect occluder is worth being explored.
Subject(s)
Aspergillosis , Humans , Male , Aspergillosis/complications , Aspergillosis/diagnosis , Aspergillosis/microbiology , Bronchoscopy , Treatment Outcome , Aspergillus/isolation & purification , Empyema, Pleural/microbiology , Empyema, Pleural/surgery , Pleural Diseases/surgery , Pleural Diseases/microbiology , Septal Occluder Device , Fistula/microbiology , Fistula/surgeryABSTRACT
OBJECTIVE: This study investigated empiric antibiotic treatment (EAT), guideline adherence, antibiotic streamlining and clinical outcomes in 1402 hospitalized children with pediatric parapneumonic effusion/pleural empyema (PPE/PE). METHODS: A nationwide surveillance study collected data on EAT, clinical course/outcome, pathogens, susceptibility testing and antibiotic streamlining of children with PPE/PE in Germany between 2010 and 2018. Subgroups were compared using χ2 test/Fisher exact test, Mann-Whitney U test and linear regression analysis adjusting for patient age where appropriate. RESULTS: Complete data on EAT were available for 1402 children. In children with monotherapy (n = 567) and in children with combination therapy of 2 antibiotics (n = 589), the most commonly used antibiotics were aminopenicillin/beta-lactamase inhibitor [138/567 (24.3%) and 102/589 (17.3%)] and cefuroxime [291/567 (51.3%) and 294/589 (49.9%)]. The most common combinations with these beta-lactams were macrolides, aminoglycosides and clindamycin. We observed no difference in clinical severity/outcome between EAT with aminopenicillin/beta-lactamase inhibitor and cefuroxime, neither when used in monotherapy nor when used in combination therapy of 2 antibiotics. Species diagnosis of Streptococcus pneumoniae (n = 192), Streptococcus pyogenes (n = 111) or Staphylococcus aureus (n = 38) in polymerase chain reaction or culture from pleural fluid or blood resulted in a switch to an appropriate narrow-spectrum beta-lactam therapy in 9.4%, 18.9 % and 5.2% of children. In a subset of children with reported bacterial susceptibility testing, penicillin resistance was reported in 3/63 (4.8%) of S. pneumoniae and methicillin resistance in S. aureus was reported in 10/32 (31.3%) of children. CONCLUSION: This study points to antibiotic overtreatment in children with PPE/PE, particularly the frequent use of combinations of antibiotics. Children receiving combinations of antibiotics did not show differences in clinical outcomes. The low rate of children with streamlined antibiotic therapy even upon pathogen detection indicates a necessity for antibiotic stewardship measures in PPE/PE and the need of investigating other potential therapeutic strategies as anti-inflammatory therapy.
Subject(s)
Anti-Bacterial Agents , Empyema, Pleural , Pleural Effusion , Humans , Anti-Bacterial Agents/therapeutic use , Germany/epidemiology , Child, Preschool , Male , Female , Child , Empyema, Pleural/drug therapy , Empyema, Pleural/microbiology , Infant , Pleural Effusion/drug therapy , Pleural Effusion/microbiology , Adolescent , Microbial Sensitivity TestsABSTRACT
OBJECTIVES: Thoracoscopy under local anaesthesia is widely performed to diagnose malignancies and infectious diseases. However, few reports have described the use of this procedure for diagnosing and treating intrathoracic infections. This study aimed to evaluate the safety and efficacy of thoracoscopy under local anaesthesia for the management of intrathoracic infections. RESULTS: Data from patients who underwent thoracoscopy procedures performed by chest physicians under local anaesthesia at our hospital between January 2018 and December 2023 were retrospectively reviewed. We analysed their demographic factors, reasons for the examinations, diseases targeted, examination lengths, anaesthetic methods used, diagnostic and treatment success rates, as well as any adverse events. Thirty patients were included. Of these, 12 (40%) had thoracoscopies to diagnose infections, and 18 (60%) had them to treat pyothorax. In terms of diagnosing pleurisy, the causative microorganism of origin was identified via thoracoscopy in only three of 12 (25.0%) patients. For diagnosing pyothorax, the causative microorganism was identified in 7 of 18 (38.9%) patients. Methicillin-resistant Staphylococcus aureus was the most common causative microorganism identified. The treatment success rates were very high, ranging between 94.4 and 100%, whereas the identification rate of the causative microorganisms behind infections was low, ranging between 25.0 and 38.9%. The most frequent adverse events included perioperative hypoxaemia and pain. There were two (6.7%) serious adverse events of grade ≥ 3, but none resulted in death. CONCLUSIONS: The efficacy of managing intrathoracic infections through thoracoscopy under local anaesthesia is commendable. Nonetheless, the diagnostic accuracy of the procedure, regarding the precise identification of the causative microorganisms responsible for intrathoracic infections, persists at a notably low level, presenting a substantial clinical hurdle.
Subject(s)
Anesthesia, Local , Thoracoscopy , Humans , Thoracoscopy/adverse effects , Thoracoscopy/methods , Male , Anesthesia, Local/methods , Anesthesia, Local/adverse effects , Female , Middle Aged , Aged , Retrospective Studies , Adult , Treatment Outcome , Aged, 80 and over , Pleurisy/microbiology , Pleurisy/surgery , Empyema, Pleural/surgery , Empyema, Pleural/microbiologyABSTRACT
Empyema poses a significant global health concern, yet identifying responsible bacteria remains elusive. Recent studies question the efficacy of conventional pleural fluid culture in accurately identifying empyema-causing bacteria. The aim of this study was to compare diagnostic capabilities of next-generation sequencing (NGS) with conventional pleural fluid culture in identifying empyema-causing bacteria. Five databases (Google Scholar, Science Direct, Cochrane, Research Gate, and PubMed) were used to search studies comparing conventional pleural fluid culture with NGS for identifying empyema-causing bacteria using keywords. Positive results identified through conventional pleural fluid culture and NGS were extracted. In addition, bacterial profiles identified by NGS were also documented. Joanna-Briggs Institute (JBI) critical appraisal tool was employed to assess quality of included studies. Descriptive analysis was employed to present outcome of interests. From five databases, three studies, with 354 patients, were included. Findings from three studies showed that NGS outperformed conventional pleural fluid culture in detecting empyema-causing bacteria even in culture-negative samples. Moreover, dominant bacterial profiles identified through NGS included Streptococcus pneumoniae, Staphylococcus aureus, and anaerobic bacteria. In conclusion, NGS outperforms conventional pleural fluid culture in detection empyema-causing bacteria, yet further studies with larger samples and broader bacterial profiles are needed to increase confidence and urgency in its adoption over conventional pleural fluid culture.
Subject(s)
High-Throughput Nucleotide Sequencing , Humans , High-Throughput Nucleotide Sequencing/methods , Empyema, Pleural/microbiology , Empyema, Pleural/diagnosis , Bacteria/genetics , Bacteria/isolation & purificationABSTRACT
OBJECTIVES: Streptococcus pyogenes causes superficial infections but can also cause deep-seated infections and toxin-mediated diseases. In the present study, phylogenetic and in silico prediction analyses were performed on an antimicrobial resistant M1UKS. pyogenes strain causing severe clinical manifestations during the current surge of invasive group A Streptococcus (iGAS) disease. METHODS: A 40-year-old patient was admitted to the hospital with fever, chest pain and fatigue. Based on the clinical and laboratory findings, a diagnosis of sepsis with disseminated intravascular coagulation, community-acquired pneumonia, pleural empyema and streptococcal toxic shock syndrome was made. Microbial identification was performed by multiplex PCR and conventional culturing. Furthermore, antimicrobial susceptibility testing, whole genome sequencing, phylogenomic analysis and in silico prediction analysis of antimicrobial resistance genes and virulence factors were performed. RESULTS: S. pyogenes isolates were detected in pleural fluid and sputum of the patient. Both isolates belonged to the M1UK lineage of the emm1/ST28 clone, being closely related with an M1UK GAS strain from Australia. They exhibited resistance to erythromycin and clindamycin and susceptibility-increased exposure to levofloxacin and carried genes encoding for protein homologues of antibiotic efflux pumps. Moreover, several virulence factors, and a previously described single-nucleotide polymorphism in the 5' transcriptional leader sequence of the ssrA gene, which enhances expression of SpeA, were detected. CONCLUSIONS: The present antimicrobial-resistant M1UKS. pyogenes strain represents the first report of this emerging lineage associated with such manifestations of iGAS disease.
Subject(s)
Anti-Bacterial Agents , Community-Acquired Infections , Empyema, Pleural , Shock, Septic , Streptococcal Infections , Streptococcus pyogenes , Humans , Streptococcus pyogenes/genetics , Streptococcus pyogenes/drug effects , Streptococcus pyogenes/isolation & purification , Shock, Septic/microbiology , Community-Acquired Infections/microbiology , Adult , Streptococcal Infections/microbiology , Empyema, Pleural/microbiology , Anti-Bacterial Agents/pharmacology , Male , Microbial Sensitivity Tests , Phylogeny , Virulence Factors/genetics , Whole Genome Sequencing , Levofloxacin/pharmacology , Levofloxacin/therapeutic use , Erythromycin/pharmacology , Clindamycin/therapeutic use , Clindamycin/pharmacologyABSTRACT
Background: Infections caused by anaerobic bacteria occur frequently and can be serious and life-threatening. Anaerobes are a rare cause of community-acquired pneumonia with Streptococcus pneumonia and respiratory viruses being the most frequently detected pathogens. We, herein, report a case of Fusobacterium/Peptostreptococcus parapneumonic effusion with empyema in a patient without risk factors for aspiration pneumonia. This case presents an opportunity to discuss an unusual case of community-acquired empyema secondary to anaerobic infection in a patient without the common risk factors for aspiration.
Case Presentation: A 59-year-old male patient without significant past medical history apart from a twenty-five-year history of smoking presented due to left flank pain and shortness of breath. Findings of a complicated parapneumonic effusion were found on imaging, resulting in surgical decortication and prolonged antibiotic therapy.
Discussion: Parapneumonic effusions and empyema are relatively common complications of pneumonia. It is important to note that the incidence of anaerobic empyema has been on the rise due to more modern culturing techniques.
Conclusion: This case highlights an unusual presentation of community-acquired empyema secondary to anaerobes without any risk factors for aspiration pneumonia. Therefore, clinicians should consider the possibility of anaerobic coverage in the treatment of community-acquired empyema in the appropriate setting.
.Subject(s)
Anti-Bacterial Agents , Community-Acquired Infections , Fusobacterium , Peptostreptococcus , Humans , Male , Middle Aged , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/microbiology , Community-Acquired Infections/drug therapy , Peptostreptococcus/isolation & purification , Fusobacterium/isolation & purification , Empyema, Pleural/microbiology , Empyema, Pleural/drug therapy , Empyema/microbiology , Fusobacterium Infections/drug therapy , Fusobacterium Infections/microbiology , Fusobacterium Infections/complications , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiologyABSTRACT
Vaping is defined as inhaling and exhaling vapour that is a product of heating a liquid or wax-like material. Electronic cigarettes (e-cigarettes) have become a popular method of smoking in the last decade and are advertised as an alternative to conventional smoking. Since the increase in e-cigarette use, various lung injury patterns have started to appear among users. Recent studies have shown an increased susceptibility to respiratory tract infections among e-cigarette/vaping product users. We present a case of pneumonia caused by Pseudomonas fluorescens complicated by rapidly developing empyema in an otherwise healthy patient.
Subject(s)
Electronic Nicotine Delivery Systems , Empyema, Pleural , Smoking Cessation , Vaping , Humans , Smokers , Smoking , Vaping/adverse effects , Empyema, Pleural/etiology , Empyema, Pleural/microbiologyABSTRACT
Background: Empyema (the presence of pus in the pleural space) is a severe complication of community-acquired pneumonia and significant cause of morbidity, but, fortunately, not mortality in children. Between 0.6 and 2% of pneumonias are complicated by empyema and the three main pathogens involved are Streptococcus pneumoniae, Staphylococcus aureus and group A Streptococcus 1,2,3,4. Optimal management in children, especially the choice of antibiotics, method of administration and duration of therapy, pleural dranage or surgery, are still a matter of debate and currently, lack of strong specific recommendations. This paper displays the study protocol for a scoping review that aims to summarize the available literature on the microbiological epidemiology, the medical and surgical treatment options, and the outcomes of pleural empyema in pediatric population. Methods: Comprehensive research combining the terms pediatric (children aged 0 to 18 years) and pleural empyema will be performed on PubMed and SCOPUS to identify all eligible studies. At first, two reviewers will screen the abstract and then their full text to determine the articles that meet the inclusion criteria. This work will be carried out independently, everyone on a different Excel spreadsheet and each researcher will be blinded to the decision of the other researcher. When the process is completed, in case of discordance, any disagreement will be identified and resolved through discussion or with help of a third author. Dissemination: The findings of this review will be published in a peer-reviewed journal.
Subject(s)
Empyema, Pleural , Humans , Empyema, Pleural/therapy , Empyema, Pleural/microbiology , Child , Child, Preschool , Infant , Adolescent , Pneumonia/microbiology , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiologyABSTRACT
Los catéteres pleurales tunelizados (indwelling pleural catheter, IPC) tienen su indicación principal en el alivio sintomático de derrames pleurales malignos. No obstante, han sido empleados también en el tratamiento sintomático de derrames pleurales benignos de diferentes etiologías. Presentamos un caso de un empiema pleural recidivante por Staphylococcus aureus en un paciente pluripatológico, que fue tratado con instilaciones intrapleurales de antibióticos a través de un IPC
Indwelling pleural catheter (IPC) is mainly indicated in the treatment of symptomatic and malignant pleural effusions. Nevertheless it have also been used in treatment of benign pleural effusions of different etiologies. We present a case of recidivant pleural empyema from Staphylococcus aureus in a pluripathologic patient, who was treated with intrapleural instilations of antibiotics through an IPC
Subject(s)
Humans , Male , Middle Aged , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Empyema, Pleural/diagnostic imaging , Empyema, Pleural/drug therapy , Staphylococcus aureus , Vancomycin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Catheterization , Empyema, Pleural/microbiology , Fatal Outcome , RecurrenceABSTRACT
ABSTRACT Objective: To highlight the pathogenicity of Streptococcus anginosus, which is rare in pediatric patients, but can cause severe infections that are known to have a better outcome when treated early with interventional procedures and prolonged antibiotic therapy. Case description: The patient is a 6-year-old boy with global developmental delay, examined in the emergency room due to fever and respiratory distress. The physical examination and diagnostic workout revealed complicated pneumonia with empyema of the left hemithorax; he started antibiotic therapy and underwent thoracic drainage. Pleural fluid cultures grew Streptococcus anginosus. On day 11, the child had a clinical deterioration with recurrence of fever, hypoxia, and respiratory distress. At this point, considering the causative agent, he was submitted to video-assisted thoracoscopic decortication, with good progress thereafter. Comments: Streptococcus anginosus is a commensal bacterium of the human oral cavity capable of causing severe systemic infections. Although reports of complicated thoracic infections with this agent are rare in the pediatric population, they have been increasing in adults. Streptococcus anginosus has a high capacity to form abscess and empyema, requiring different therapeutic approaches when compared to complicated pneumonia caused by other agents.
RESUMO Objetivo: Alertar para a patogenicidade do Streptococcus anginosus que, apesar de raro em pediatria, pode causar infeções graves que necessitam de tratamento invasivo e antibioterapia de longo curso para obter um melhor prognóstico. Descrição do caso: Criança de seis anos, com atraso do desenvolvimento psicomotor, avaliado no serviço de urgência por febre e dificuldade respiratória. O exame físico, juntamente com os exames complementares, revelou uma pneumonia complicada com empiema no hemitórax esquerdo, tendo iniciado antibioterapia e sido submetido à drenagem do líquido pleural. Foi identificado Streptococcus anginosus nesse líquido. No 11º dia de doença, a criança agravou o seu estado clínico, com recidiva da febre, hipoxemia e dificuldade respiratória. Considerando-se o microrganismo identificado, o paciente foi submetido à decorticação pulmonar por videotoracoscopia, com boa evolução clínica posterior. Comentários: Streptococcus anginosus é uma bactéria comensal da cavidade oral humana, que pode causar infecções sistêmicas graves. Apesar de serem raros os casos descritos em pediatria, têm sido cada vez mais descritas infecções torácicas complicadas em adultos. Esse microrganismo também tem a capacidade de formar abcessos e empiemas, que precisam de intervenções terapêuticas diferentes, quando comparados a pneumonias complicadas causadas por outros agentes.
Subject(s)
Humans , Male , Child , Streptococcal Infections/complications , Empyema, Pleural/microbiology , Pneumonia, Bacterial/microbiology , Streptococcus anginosus , Streptococcal Infections/therapy , Streptococcal Infections/diagnostic imaging , Drainage , Empyema, Pleural/therapy , Empyema, Pleural/diagnostic imaging , Pneumonia, Bacterial/therapy , Pneumonia, Bacterial/diagnostic imaging , Thoracic Surgery, Video-Assisted , Neurodevelopmental Disorders/complications , Anti-Bacterial Agents/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Empyema, Pleural/microbiology , Gram-Positive Bacterial Infections/complications , Leuconostoc , Streptococcal Infections/complications , Streptococcus mitis , Streptococcus oralisSubject(s)
Humans , Male , Middle Aged , Empyema, Pleural/microbiology , Clostridium Infections/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Clostridium septicum , Lung Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Empyema, Pleural/diagnostic imaging , Clostridium Infections/complications , Fatal Outcome , Carcinoma, Non-Small-Cell Lung/complications , Lung Neoplasms/complicationsABSTRACT
Abstract Purpose: To evaluate the concentration of transforming growth factor beta 1 (TGFB1) levels in a rat pleural effusion obtained by inoculation of intrapleural bacteria or turpentine through thoracentesis. Methods: Thirty-Nine Wistar rats were divided into three groups: Staphylococcus aureus (SA, n = 17); Streptococcus pneumoniae (SP, n = 12); and turpentine (control, n = 10). Pleural fluid was collected through ultrasound-guided thoracentesis 12 h, 24 h, and 36 h after instillation of bacteria or turpentine. Levels of TGFB1 were measured in pleural fluid. Results: At 12 h, mean TGFB1concentrations were 5.3450 pg/mL in the SA group, 5.3449 pg/mL in the SP group, and 5.3450 pg/mL in controls. At 24 h, they were 4.6700 pg/mL in the SA group, 4.6700 pg/mL in the SP group, and 4.6700 pg/mL in controls. At 36 h, they were 4.6699 pg/mL in the SA group and in control. No difference was observed among the groups in mean TGFB1concentration (p = 0.12); however, a significant intragroup reduction in mean TGFB1 was observed between 12 and 24 h (p < 0.01). Conclusion: The transforming growth factor beta 1 concentrations were not useful as a diagnostic tool or an early marker of infected pleural effusion.
Subject(s)
Animals , Male , Rats , Pleural Effusion/diagnosis , Empyema, Pleural/diagnosis , Transforming Growth Factor beta1/analysis , Pleural Effusion/complications , Bacteria/pathogenicity , Biomarkers/analysis , Empyema, Pleural/complications , Empyema, Pleural/microbiology , Rats, Wistar , Disease Models, AnimalABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Empyema, Pleural/microbiology , Corynebacterium/pathogenicity , Corynebacterium Infections/microbiology , Thoracic Wall/pathology , Pleural Effusion/microbiologyABSTRACT
No disponible